


**Product Name** : GDC-0810  
**Cat. No.** : PC-43264  
**CAS No.** : 1365888-06-7  
**Molecular Formula** : C<sub>26</sub>H<sub>20</sub>ClFN<sub>2</sub>O<sub>2</sub>  
**Molecular Weight** : 446.9006  
**Target** : Estrogen Receptor/ERR  
**Solubility** : DMSO: ≥ 30 mg/mL



## Biological Activity

GDC-0810 (ARN-810, Brilanestrant) is a non-steroidal, orally bioavailable selective estrogen receptor degrader (SERD) with IC<sub>50</sub> of 0.7 nM (ER- $\alpha$  degradation), binds to ER $\alpha$  and ER $\beta$  with with K<sub>i</sub> of 3.8 and 3.7 nM, respectively; dually antagonizes and induces proteasome-dependent degradation of ER $\alpha$ , exhibits robust in vitro activity against a variety of human breast cancer cell lines (MCF7 cell IC<sub>50</sub>=25 nM); demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer models.

Breast Cancer

Phase 1 Discontinued

## References

Lai A, et al. J Med Chem. 2015 Jun 25;58(12):4888-904.

Joseph JD, et al. Elife. 2016 Jul 13;5. pii: e15828.

Wang Y, et al. Clin Cancer Res. 2017 Jun 15;23(12):3053-3060.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com